Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Biologics Active Pharmaceutical Ingredient (API) Market Worth $101.8 Billion by 2030, Witnessing 8.8% CAGR

globenewswire.com
PFE Pfizer Inc is mentioned as a major player in the growing Biologics Active Pharmaceutical Ingredient (API) market, indicating potential involvement and benefit from market expansion. ABBV AbbVie Inc is listed as a major player in the Biologics API market, suggesting it is positioned to benefit from the market's projected growth and trends. AZN AstraZeneca PLC is identified as a major player in the expanding Biologics API market, implying potential for growth and increased revenue. BMY Bristol-Myers Squibb Company is named as a key participant in the Biologics API market, which is experiencing significant growth and is projected to expand further. TMO Thermo Fisher Scientific Inc is listed as a major player in the Biologics API market, indicating potential to benefit from the market's growth and technological advancements. LLY Eli Lilly and Company is mentioned as a major player in the Biologics API market, which is projected to grow significantly, suggesting potential for increased business. AMGN Amgen Inc is identified as a major player in the expanding Biologics API market, suggesting it is well-positioned to capitalize on market growth trends. DHR Danaher Corporation is listed as a major player in the Biologics API market, which is experiencing robust growth, indicating potential for increased demand for its products/services.

Biologics Active Pharmaceutical Ingredient (API) Market Worth $101.8 Billion by 2030, Witnessing 8.8% CAGR Dublin, April 23, 2026 (GLOBE NEWSWIRE) -- The "Biologics Active Pharmaceutical Ingredient (API) Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The biologics active pharmaceutical ingredient (API) market has experienced significant growth in recent years, with projections indicating further expansion. As reported, the market size increased from $66.82 billion in 2025 to $72.57 billion in 2026, at a compound annual growth rate (CAGR) of 8.6%. This burgeoning growth is largely attributed to the rising prevalence of chronic and autoimmune diseases, the expanding development pipelines of monoclonal antibodies, and the growth of recombinant protein therapeutics. Furthermore, substantial investments in biologics manufacturing infrastructure and increased outsourcing to contract manufacturing organizations (CMOs) have fueled market growth.

Looking ahead, the market is expected to reach $101.84 billion by 2030 with a CAGR of 8.8%. Several factors are anticipated to contribute to this robust growth, including advancements in cell and gene therapies, heightened demand for personalized biologic medicines, and the expansion of commercial-scale biologics production. Additional driving forces include the emphasis on process scalability and consistency, along with regulatory focus on API quality and traceability. Key trends expected to shape the forecast period include the adoption of single-use bioprocessing systems, demand for high-purity APIs, and a focus on cold chain integrity and advanced purification technologies.

The surge in personalized medicine is a significant driver of the biologics API market growth. Personalized medicine tailors disease prevention, diagnosis, and treatment strategies to an individual's genetic profile, which improves clinical outcomes and minimizes adverse drug reactions. Reports indicate that in February 2024, 16 new personalized treatments for rare diseases had been FDA-approved, up from six approvals in 2022. This increasing demand bolsters the need for precise, patient-specific biologic compounds, thus driving higher demand for high-quality biologic APIs.

In terms of industry dynamics, companies are enhancing drug efficacy and accessibility through the development of advanced solutions, such as biosimilar development platforms. For instance, Enzene Biosciences, a biopharmaceutical company, launched its biosimilar version of adalimumab in March 2023. This cost-effective solution provides a comparable clinical performance to the originator product, utilizing advanced bioprocessing and analytical techniques to meet regulatory standards and maintain batch quality.

On the mergers and acquisitions front, HAS Healthcare Advanced Synthesis SA acquired Cerbios-Pharma SA in March 2025, expanding its CDMO capabilities to include biologics and hybrid drug substances. This acquisition supports the end-to-end development and manufacturing of complex APIs, such as recombinant proteins and antibody-drug conjugates, strengthening their market presence.

The market is characterized by major players including F Hoffmann-La Roche Ltd, Pfizer Inc, AbbVie Inc, Sanofi SA, Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc, GSK plc, Eli Lilly and Company, Amgen Inc, Danaher Corporation, among others.

Reasons to Purchase

This report covers essential aspects such as market characteristics, size and growth, segmentation, regional breakdowns, total addressable market, and attractiveness scoring.

Report Scope:

Geographical Coverage: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Regions: Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Time Series: Five years historic and ten years forecast.

Data Format: Market ratios, growth comparisons, GDP proportions, expenditure per capita.

Key Attributes

The companies featured in this Biologics Active Pharmaceutical Ingredient (API) market report include:

For more information about this report visit https://www.researchandmarkets.com/r/vpdrio

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment